Jehan Tamboowalla is a seasoned industry executive bringing more than 20 years of Product Launch, Commercial, and R&D experience spanning Ophthalmology, Immunology and Cell & Gene Therapies.  Prior to joining Visus Therapeutics as Senior Vice President, Marketing and Business Development, Jehan was VP, Head of New Products, Ophthalmology at Novartis.  At Novartis, Jehan and his team led the commercial evaluations of numerous external partnering and acquisition opportunities including, most recently, the successful acquisition of gene-therapy company, Gyroscope Therapeutics.  Other notable transactions included securing global (ex-US) rights to Luxturna® from Spark Therapeutics, and in-licensing Xiidra® from Takeda Pharmaceuticals.  Jehan brings a deep understanding of commercial case development and valuations having been the commercial lead on 40+ due diligences.  Prior to joining Novartis, Jehan was Managing Director at Red Team Associates, a boutique consulting firm, specialized in working with emerging biopharma, private equity, and venture capital clients.  Jehan’s industry experience includes multiple product launches and marketing roles of increasing responsibility at Bayer AG, Bausch & Lomb, and GSK.  Jehan continues to coach and mentor emerging leaders in Pharma and Biotech, and he continues to be a strategic C-level and board advisor to VCs and biotech companies.

Jehan holds BS and MS degrees in Biotechnology and Biology from the Worcester Polytechnic Institute, and an International MBA from Thunderbird.